Business · Markets · 1 day ago
Telix and Clinuvel offer different profiles for ASX healthcare investors
Telix Pharmaceuticals and Clinuvel Pharmaceuticals are Australian biotech companies with international businesses.
Telix develops cancer imaging and treatment products using targeted radiation, and its Illuccix product is approved for prostate cancer imaging in Australia, the United States and Canada.
Clinuvel is best known for SCENESSE, a treatment for people with rare genetic disorders that cause extreme sensitivity to sunlight.
By 7 October 2026, Telix had a market value of $5.40 billion and its shares were up 37.6% for the year, while Clinuvel had a market value of $413.5 million and its shares were down 34.4%.
Telix does not pay a dividend and had a much higher price-to-earnings ratio, while Clinuvel paid a fully franked dividend and had a lower ratio.
These differences mean Telix may appeal more to investors seeking growth, while Clinuvel offers a dividend and a lower valuation.
The comparison's author leans toward Telix, citing its size, cancer pipeline and share-price momentum, while noting that its valuation reflects high expectations.
Telix Pharmaceuticals had a market capitalisation of $5.40 billion, compared with $413.51 million for Clinuvel Pharmaceuticals.
Telix shares were up 37.6% year to date, while Clinuvel shares were down 34.4% as of 7 October 2026.
Telix had a price-to-earnings ratio of 108.53, far above Clinuvel’s 12.17.
Clinuvel paid a fully franked dividend yield of 0.62%, while Telix paid no dividend.
The article’s author said they would lean towards Telix for a $1,000 investment, citing its size, cancer-treatment pipeline and share-price momentum.
- Who
- Telix Pharmaceuticals and Clinuvel Pharmaceuticals, two Australian biotech companies.
- What
- The article compares their market values, share-price performance, valuations and dividends.
- When
- Share prices and year-to-date returns were reported through 7 October 2026; the article was published on 10 October 2026.
- Where
- Both companies are Australian and have international operations.
- Why
- The comparison considers which company might suit an investor seeking growth, value or income.
This story does not have two clearly opposing sides.
I'd lean toward Telix.
Telix shares closed at $15.87 and Clinuvel shares closed at $8.20.
Motley Fool AU published its comparison of Telix and Clinuvel.
- Telix market capitalisation
- $5.40 billion
- Clinuvel market capitalisation
- $413.51 million
- Telix year-to-date return
- 37.6% through 7 October 2026
- Clinuvel year-to-date return
- -34.4% through 7 October 2026
- Telix and Clinuvel P/E ratios
- 108.53 and 12.17
- Clinuvel dividend yield
- 0.62%, fully franked
Sources
Related news
Five ASX 200 shares stand out for quality and value
Kaoko reports copper-silver discovery at Namibia's Chalkos project
Business News subscription page outlines Western Australia-focused services
Western Australia’s EPA to review proposed Kimberley gas project
EOS wins £370m counter-drone contract, Bell Potter sees 36% upside
Adidas sues Australian fashion label White Fox over four-stripe clothing design
Bell Potter keeps its buy rating on Life360 after shares fall nearly 40%
McKinsey removes Australian partner from leadership role after comments about women executives
DroneShield remains the most shorted ASX share
Harvey Norman looks better value than Temple & Webster in comparison
Birdsville Track closure cuts off tourism and freight in the outback
